Title :

Factor VIII and IX assays for post‐infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT)

Author(s) :

Jeanpierre, Emmanuelle [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Pouplard, Claire [Auteur]
Service d'hématologie [Tours]
Lasne, Dominique [Auteur]
Hémostase, Inflammation, Thrombose [HITH - U1176 Inserm - CHU Bicêtre]
Hôpital Necker - Enfants Malades [AP-HP]
Le Cam Duchez, Véronique [Auteur]
UNIROUEN - UFR Santé [UNIROUEN UFR Santé]
Eschwege, Valérie [Auteur]
Service d'Hématologie [CHRU Nancy]
Flaujac, Claire [Auteur]
Galinat, Hubert [Auteur]
Harzallah, Ines [Auteur]
Proulle, Valérie [Auteur]
Hémostase, Inflammation, Thrombose [HITH - U1176 Inserm - CHU Bicêtre]
Smahi, Motalib [Auteur]
Sobas, Frédéric [Auteur]
Hospices Civils de Lyon [HCL]
Stepina, Nataliia [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Toulon, Pierre [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Voisin, Sophie [Auteur]
Institut cellule souche et cerveau / Stem Cell and Brain Research Institute [SBRI]
Ternisien, Catherine [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Nougier, Christophe [Auteur]
Hospices Civils de Lyon [HCL]

Journal title :

European Journal of Haematology

Pages :

103-115

Publisher :

Wiley

Publication date :

2020-05-27

ISSN :

0902-4441

HAL domain(s) :

Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Hématologie

English abstract : [en]

Abstract Replacement therapy with plasma‐derived or recombinant FVIII and FIX (pdFVIII/pdFIX or rFVIII/rFIX) concentrates is the standard of treatment in patients with haemophilia A and B, respectively. Measurement of ...
Show more >Abstract Replacement therapy with plasma‐derived or recombinant FVIII and FIX (pdFVIII/pdFIX or rFVIII/rFIX) concentrates is the standard of treatment in patients with haemophilia A and B, respectively. Measurement of factor VIII (FVIII:C) or factor IX (FIX:C) levels can be done by one‐stage clotting assay (OSA) or chromogenic substrate assay (CSA). The French study group on the Biology of Hemorrhagic Diseases (a collaborative group of the GFHT and MHEMO network) presents a literature review and proposals for the monitoring of FVIII:C and FIX:C levels in treated haemophilia A and B patients, respectively. The use of CSA is recommended for the monitoring of patients treated with pdFVIII or rFVIII including extended half‐life (EHL) rFVIII. Except for rFVIII‐Fc, great caution is required when measuring FVIII:C levels by OSA in patients substituted by EHL‐rFVIII. The OSA is recommended for the monitoring of patients treated with pdFIX or rFIX. Large discordances in the FIX:C levels measured for extended half‐life rFIX (EHL‐rFIX), depending on the method and reagents used, must lead to great attention when OSA is used for measuring FIX:C levels in patients substituted by EHL‐rFIX. Data of most of recent studies, obtained with spiked plasmas, deserve to be confirmed in plasma samples of treated patients.Show less >

Language :

Anglais

Popular science :

Non

Collections :

• Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011

Source :

Harvested from HAL